Ruth is a clinical research professional who brings to the Nuvalent team more than 20 years of experience in oncology drug development spanning across research and development. She joined the team in November 2020 and is currently responsible for oversight of trial execution, clinical compliance, and outsourcing strategy.
Before joining Nuvalent in this role, Ruth was an independent clinical operations consultant, where she collaborated closely with the Nuvalent team. Prior to this, Ruth served as head of clinical operations at Vigeo Therapeutics where she was responsible for leading their inaugural oncology study. During her tenure at BeiGene, Ruth was accountable for the operational program strategy, oversight and execution of US led global hematology studies. At Infinity Pharmaceuticals Ruth managed their registrational study and acted as the NDA submission SME for a program that later resulted in FDA approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. While at Takeda Pharmaceuticals, Ruth held a position in the early phase oncology group where she managed multiple first-in-human studies. Before her transition to clinical operations Ruth was an accomplished medicinal chemist and held positions at Millennium Pharmaceuticals and Cambridge Discovery Chemistry, focusing on the design and synthesis of lead oncology compounds.
Ruth earned her bachelor’s degree in chemistry at The University of Southampton, UK.